Background
==========

Facial clefting is one of the most common malformations in humans. Significant differences between populations in the prevalence of cleft lip or palate (CL/P) have been reported, with higher rates found in Asians and American Indians than those observed in Caucasians and Africans. Palate formation is complex, and there are numerous potential untoward possibilities, the most common being delayed shelf horizontalization and inadequate shelf growth \[[@B1]\].

Epidemiologic studies suggest that a number of environmental factors have been examined as risk factors for CL/P, including maternal smoking, exposure to antiepileptic drugs, antiemetic agents and vitamin use during the periconceptual period, maternal metabolic factors, alcohol consumption and exposure to agricultural chemicals \[[@B2]\]. Several studies have suggested that maternal cigarette smoking increased the risk of delivering infants with orofacial clefts \[[@B3]-[@B6]\]. It has previously been shown that maternal periconceptional intake of multivitamins containing folic acid decreased the occurrence of CL/P \[[@B6]-[@B8]\]. However, there is a study showing the different results \[[@B9]\]. A case--control study showed that CL/P was associated with maternal alcohol consumption \[[@B10]\]. However, Christensen and colleagues found that before the pregnancy there were fewer case mothers drinking alcohol than control mothers \[[@B11]\].

The epidemiologic characteristics and risk factors of CL/P are not clear. There is also a strong genetic component to oral clefts. The host susceptibility factors may play an important role in the development of CL/P. Ardinger and colleagues performed the first study to use a case--control design to test candidate genes \[[@B12]\]. They found a significantly statistical association between CL/P and two of 12 markers in five genes, with an intronic *Taq1* marker in the transforming growth factor alpha (TGFA) gene showing the strongest association. TGFA encoded by a gene mapped at 2p13, is a secretion protein that binds to the epidermal growth factor receptor (EGFR) and is situated at the palate epithelium during palate closing \[[@B13]\]. TGFA may function as a normal embryonic version of EGF-related growth factor \[[@B14]\]. EGF/TGFA and glucocorticoids are believed to regulate the proliferation and differentiation of palatal epithelial cells both *in vitro* and *in vivo*. Moreover, the continued presence of EGF inhibits the fusion process; TGFA is likely to have similar effects. These biological studies suggest that mutations in the TGFA gene might contribute to the development of CL/P, especially for those mutations that affect the timing of the tissue-specific expression of this gene.

The TGFA gene shows a restriction fragment length polymorphism when treated with Taq I restriction enzyme. The mutant allele shows a four-base (TAAT) deletion. In this case, it shows a 178-base pair (bp) C1 allele and a 174-bp C2 allele \[[@B15]\]. TGFA Taq I polymorphism is located at intron 5 and has 602 bp in the 59 direction of the acceptor site of exon 6 \[[@B16]\]. For this polymorphism, C1C1 is wild genotype, C1C2 is heterozygote genotype, and C2C2 is homozygote mutation genotype. In most studies, there are different forms of comparisons such as heterozygote comparison (C1C2 vs. C1C1), homozygote comparison (C2C2 vs C1C1), dominant model (C1C2 + C2C2 vs C1C1), recessive model (C2C2 vs C1C2 + C1C1) and allelic model (C2 vs C1). Ardinger and colleagues first reported association between the Taq I polymorphisms at the TGFA locus and CL/P susceptibility in a case--control study \[[@B12]\]. This finding has since been replicated in some studies \[[@B6],[@B15],[@B17]-[@B23]\]. However, there are still controversies of the effect of TGFA polymorphism on the predisposition of this malformation \[[@B24]-[@B35]\].

The above inconsistent conclusions in the findings of the studies may be attributed to the size of the samples, the ethnic of the sample population and other reasons. In order to contribute to a better understanding of the role of this gene in the occurrence of cleft lip, cleft lip, or cleft lip and palate, we perform an updated meta-analysis on all available case--control studies, combining data together to reach a larger sample size, to get more statistical power to evaluate the association between CL/P susceptibility and TGFA Taq I polymorphism. Understanding the genetic background and etiology of CL/P is essential for both the risk assessment and findings of effective methods for prevention and treatment.

Methods
=======

Data sources
------------

We retrieved the articles using the following terms "Transforming growth factor alpha or TGFA" and "cleft lip or cleft palate or cleft lip and palate" from PubMed, Embase, ISI Web of Science and SCOPUS (Last search was updated on October 2013). There was no any language restriction and the age of participants was not considered as selection criteria. We evaluated potentially relevant publications by examining their titles and abstracts and all studies matching the eligible criteria were retrieved.

Study selection and data extraction
-----------------------------------

Eligible studies were selected according to the following explicit inclusion criteria: (a) evaluation of the TGFA Taq I polymorphism and CL/P risks, (b) using the methodology of a case--control study to keep the homogeneity between included studies in the meta-analysis.

Duplicate and obviously unrelated articles were eliminated by a single author (C.F.). Abstracts of the remaining articles were examined independently by two authors (C.F. and E.Z.) to determine whether the full-text article should be sought. When there were disagreements between CF and EZ in selecting papers, the third author (L.L.) would assess the articles and make the final decision with CF and EZ. A four-phase flow diagram according to Systematic Reviews (<http://www.prisma-statement.org/>) was shown in Figure [1](#F1){ref-type="fig"}. We have used the Newcastle-Ottawa Scale (NOS), suggested by Cochrane Collaboration, for assessing the quality of each included study in the present meta-analysis. The following information was obtained from each publication: first author's name, publication year, country origin, ethnicity, case characteristics, total number of cases and controls, numbers of each group with TGFA Taq I genotypes, respectively.

![Flow chart of the study selection process.](1472-6831-14-88-1){#F1}

Statistical methods
-------------------

The odds ratios (ORs) and their 95% confidence intervals (95% CIs) were calculated to assess the association between TGFA Taq I polymorphism and CL/P. Pooled ORs were obtained from combination of single study by heterozygote comparison (C1C2 vs. C1C1), homozygote comparison (C2C2 vs C1C1), dominant model (C1C2 + C2C2 vs C1C1), recessive model (C2C2 vs C1C2 + C1C1) and allelic model (C2 vs C1), respectively. These comparisons were used to provide more information about the relationship between the polymorphism and the disease, assess the association in different point of view and validate the association by many ways, as well as offer the data for further study on the gene expression. Meta-analyses were performed on the total data set and separately for the source of control and disease type. We investigated the between-study heterogeneity by the Cochran's Q test and quantified by I2. To obtain summary statistics for ORs of the polymorphism and disease, we performed initial analyses with a fixed-effect model and confirmatory analyses with a random-effect model if there was significant heterogeneity. If there is no heterogeneity, the fixed and random effects models produce similar results, and, if not, the random-effect model usually produces wider CIs than the fixed-effect model. If the P value is \>0.05 of the Q test, the summary OR estimate of each study was calculated by the fixed-effect model. Otherwise, the random-effect model was used.

We assessed potential publication bias by examining funnel plots and using Egger's test \[[@B36],[@B37]\]. A funnel plot is a graph designed to check for the existence of publication bias in systematic reviews and meta-analyses. In the absence of publication bias, it assumes that the largest studies will be plotted near the average, and smaller studies will be spread evenly on both sides of the average, creating a roughly funnel-shaped distribution. Deviation from this shape can indicate publication bias. This approach is very simple to use but, sometimes, we may have doubts about the funnel asymmetry, especially if the number of studies is small. In addition, the funnel may be asymmetric due to a deficient quality of studies or because we are dealing with interventions whose effect varies with the sample of each study. For these situations, Egger's linear regression could be used. Egger's test plots the regression line between precision of the studies (independent variable) and the standardized effect (dependent variable). When there isn't publication bias the regression line originates in the Y-axis zero. So much further away from zero, further evidence of publication bias. The significance of the intercept was determined by the *t*-test as suggested by Egger's test. All of P values were two-sided and all analyses were performed using the Stata software version 11.0 (Stata Corp, College station, TX).

Results
=======

Detailed characteristics of each study are summarized in Table [1](#T1){ref-type="table"}. A total of 20 case--control studies including 3824 cases and 7710 controls contributed to the analysis. The subjects in the study were population of Caucasian, African, Hispanic and Asian. There are some studies including more than one ethnic population. There were 14 studies containing Europeans, 4 studies including Hispanics, 3 studies involving Africans and 2 studies comprising Asians. For the Europeans, Hispanics, Africans and Asians, sample sizes ranged from 25 to 1525, 90 to 921, 17 to 69 and 12 to 100, respectively. The total sample size were 2897 cases and 6806 controls for the Europeans, 853 cases and 753 controls for the Hispanics, 41 cases and 72 controls for the Africans and 33 cases and 79 controls for the Asians. The types of controls included population-based, hospital-based and unrelated family members.

###### 

Characteristics of the studies included in the meta-analysis

  **Author, year**            **Country**   **Ethnicity**   **Clip type**   **Control characteristics**   **No. (case/control)**   **Case**   **Control**                                     
  --------------------------- ------------- --------------- --------------- ----------------------------- ------------------------ ---------- ------------- ---- ---------- ----- ------ ---- ----------
  BEATY \[[@B31]\]            USA           Caucasian       CP              HB                            42/135                   \-         \-            \-   78/6       \-    \-     \-   248/22
                                            Caucasian       CL/P            HB                            86/135                   \-         \-            \-   163/9      \-    \-     \-   248/22
                                            African         CP              HB                            13/135                   \-         \-            \-   24/2       \-    \-     \-   248/22
                                            African         CL/P            HB                            11/135                   \-         \-            \-   22/0       \-    \-     \-   248/22
  TANABE \[[@B15]\]           Japan         Asian           CL/P            HB                            28/73                    \-         \-            \-   49/7       \-    \-     \-   129/17
  **Lilian Jara**\[[@B21]\]   Chile         Hispanic        CL/P            HB                            39/51                    33         6             0    72/6       44    6      1    94/8
  Sassani \[[@B19]\]          USA           Caucasian       CL/P            HB                            81/84                    54         26            1    134/28     70    13     1    153/15
                                            Asian           CL/P            HB                            6/6                      4          2             0    10/2       4     2      0    10/2
                                            African         CL/P            HB                            10/7                     4          5             1    13/7       4     3      0    11/3
  Ardinger \[[@B12]\]         USA           Caucasian       CL/P            HB                            78/98                    59         17            2    135/21     89    8      1    186/10
  Shiang \[[@B20]\]           USA           Caucasian       CP              HB                            43/170                   \-         \-            \-   69/17      \-    \-     \-   311/29
  Hwang \[[@B22]\]            USA           Caucasian       CP              HB                            69/284                   49         20            0    118/20     239   44     1    522/46
                                            Caucasian       CL/P            HB                            114/284                  93         19            2    205/23     239   44     1    522/46
  ROMITTI \[[@B30]\]          USA           Caucasian       CP              PB                            51/295                   41         10\*          \-   \-         235   60\*   \-   \-
                                            Caucasian       CL/P            PB                            118/295                  96         22\*          \-   \-         235   60\*   \-   \-
  Hecht \[[@B24]\]            USA           Caucasian       CL/P            UFM                           12/13                    11         1             0    23/1       10    2      1    22/4
  Chenevix \[[@B18]\]         Australia     Caucasian       CL/P            HB                            117/113                  84         30            3    198/36     94    17     2    205/21
  Holder \[[@B17]\]           UK            Caucasian       CL/P            HB                            60/60                    36         14            5    86/24      55    5      0    115/5
  **CHENEVIX**\[[@B29]\]      Australia     Caucasian       CL/P            HB                            96/100                   66         27            3    159/33     90    9      1    189/11
  Stoll \[[@B25]\]            France        Caucasian       CL/P            HB                            98/99                    \-         \-            \-   187/10     \-    \-     \-   184/14
                                            Caucasian       CP              HB                            57/99                    \-         \-            \-   104/10     \-    \-     \-   184/14
  Christensen \[[@B11]\]      Denmark       Caucasian       CP              PB                            65/457                   49         15            1    113/17     344   102    11   790/124
                                            Caucasian       CL/P            PB                            191/457                  145        45            1    335/47     344   102    11   790/124
  SHAW \[[@B6]\]              USA           Caucasian       CP              PB                            114/379                  87         27\*          \-   \-         321   58\*   \-   \-
                                            Hispanic        CP              PB                            35/175                   34         1\*           \-   \-         164   11\*   \-   \-
                                            African         CP              PB                            7/20                     6          1\*           \-   \-         18    2\*    \-   \-
                                            Caucasian       CL/P            PB                            245/379                  212        33\*          \-   \-         321   58\*   \-   \-
                                            Hispanic        CL/P            PB                            103/175                  94         9\*           \-   \-         164   11\*   \-   \-
                                            African         CL/P            PB                            12/20                    11         1\*           \-   \-         18    2\*    \-   \-
  Beaty \[[@B26]\]            USA           Caucasian       CP              HB                            51/87                    44         6             1    94/8       79    8      0    166/8
                                            Caucasian       CL              HB                            26/87                    21         5             0    47/5       79    8      0    166/8
                                            Caucasian       CL/P            HB                            53/87                    48         5             0    101/5      79    8      0    166/8
                                            African         CP              HB                            12/45                    10         2             0    22/2       43    2      0    88/2
                                            African         CL              HB                            2/45                     2          0             0    4/0        43    2      0    88/2
                                            African         CL/P            HB                            10/45                    9          1             0    19/1       43    2      0    88/2
  Bertoja \[[@B34]\]          Brazil        Hispanic        CL/P            HB                            140/142                  114        25            1    253/27     121   21     0    263/21
  PASSOS-BUENO \[[@B32]\]     Brazil        Hispanic        CL/P            HB                            536/385                  484        51            1    1019/53    344   41     0    729/41
  Lidral \[[@B28]\]           USA           Caucasian       CL/P            PB                            182/251                  \-         \-            \-   327/37     \-    \-     \-   449/53
                                            Caucasian       CP              PB                            62/251                   \-         \-            \-   109/15     \-    \-     \-   449/53
  Lidral \[[@B27]\]           USA           Caucasian       CL/P            PB                            652/776                  \-         \-            \-   1204/100   \-    \-     \-   1436/116
                                            Caucasian       CP              PB                            97/776                   \-         \-            \-   176/18     \-    \-     \-   1436/116

*CL*: clip lip, *CL/P*: clip lip and palate, *CP*: clip palate, *PB*: population-based control group, *HB*: hospital-based control group, *UFM*: unrelated family members control group.

C1C1, C1C2, C2C2: genotype, C1/C2: allele frequency.

\*The sum of C1C2 and C2C2.

NOS results suggested that all of the included studies are high level quality with the score \>6.

Association between the genotypes of TGFA Taq1 and CL/P risk
------------------------------------------------------------

A summary of the meta-analysis findings of the association between TGFA Taq I and CL/P risk is provided in Table [2](#T2){ref-type="table"}. Meta-analysis showed statistically significant association between TGFA Taq I polymorphism and CL/P risk in heterozygote comparison, dominant and allelic model (C1C2 vs C1C1: OR = 1.67, 95% CI = 1.23-2.25, P = 0.009 for heterogeneity, I^2^ = 55.8%; C2C2 + C1C2 vs C1C1: OR = 1.52, 95% CI = 1.15-2.01, P \< 0.001 for heterogeneity, I^2^ = 64.7%; C2 vs C1: OR = 1.41, 95% CI = 1.12-1.78, P \< 0.001 for heterogeneity, I^2^ = 65.2%), but not in the homozygote and recessive model (C2C2 vs C1C1: OR = 1.57, 95% CI = 0.87-2.83, P = 0.525 for heterogeneity, I^2^ = 0.0%; C2C2 vs C1C2 + C1C1: OR = 1.43, 95% CI = 0.79-2.59, P = 0.634 for heterogeneity, I^2^ = 0.0%). Meta-analysis results of the association between TGFA Taq I polymorphism and CL/P risk under the heterozygote comparison model (C1C2 versus C1C1), the dominant model (C1C2 + C2C2 versus C1C1), and the allelic model (C2 versus C1) were also shown in Figure [2](#F2){ref-type="fig"}, Figure [3](#F3){ref-type="fig"} and Figure [4](#F4){ref-type="fig"}, respectively.

###### 

Association between TGFA Taq1 polymorphism and CL/P risk

  **Model**              **Number of studies**   **Fixed effect**     **Random effect**    **Phet**   **I-squared (%)**
  ---------------------- ----------------------- -------------------- -------------------- ---------- -------------------
  C1C2 vs. C1C1          12                      1.46 \[1.22,1.75\]   1.67 \[1.23,2.25\]   0.009      55.8
  C2C2 vs. C1C1          12                      1.57 \[0.87,2.83\]   1.56 \[0.78,3.16\]   0.525      0.0
  C1C2 + C2C2 vs. C1C1   14                      1.33 \[1.14,1.54\]   1.52 \[1.15,2.01\]   0.000      64.7
  C2C2 vs. C1C2 + C1C1   12                      1.43 \[0.79,2.59\]   1.42 \[0.70,2.85\]   0.634      0.0
  C2 vs. C1              18                      1.26 \[1.12,1.43\]   1.41 \[1.12,1.78\]   0.000      65.2

![Forest plot of cancer risk associated with TGFA Taq I polymorphism under the heterozygote comparison model (C1C2 versus C1C1).](1472-6831-14-88-2){#F2}

![Forest plot of cancer risk associated with TGFA Taq I polymorphism under the dominant model (C1C2 + C2C2 versus C1C1).](1472-6831-14-88-3){#F3}

![Forest plot of cancer risk associated with TGFA Taq I polymorphism under the allelic model (C2 versus C1).](1472-6831-14-88-4){#F4}

Stratified meta-analysis
------------------------

Stratified analyses were conducted by ethnicity, source of control and disease type. Pooled ORs and 95% CIs of stratified meta-analysis are showed in Table [3](#T3){ref-type="table"}. In the subgroup analysis by ethnicity, significantly increased CL/P risks were found among Caucasian (C1C2 vs C1C1: OR = 1.95, 95% CI = 1.34-2.86; C2C2 + C1C2 vs C1C1: OR = 1.68, 95% CI = 1.18-2.38; C2 vs C1: OR = 1.52, 95% CI = 1.14-2.02). No significantly evaluated risk was found among African and Hispanic population in any of the genetic models.

###### 

Pooled ORs and 95% CIs of stratified meta-analysis

  **Subgroup**            **Genotype**           **No of studies**   **Test of association**   **Test of heterogeneity**                       
  ----------------------- ---------------------- ------------------- ------------------------- --------------------------- ------- --- ------- ------
  **Ethnicity**                                                                                                                                
  African                                                                                                                                      
                          C1C2 + C2C2 vs. C1C1   3                   1.92 \[0.63,1.90\]        1.14                        0.253   F   0.754   0.0
                          C2 vs. C1              3                   1.15 \[0.50,2.66\]        0.33                        0.741   F   0.254   26.9
  Caucasian                                                                                                                                    
                          C1C2 vs. C1C1          9                   1.95 \[1.34,2.86\]\*      3.48                        0.001   R   0.016   57.3
                          C2C2 vs. C1C1          9                   1.50 \[0.79,2.84\]        1.25                        0.211   F   0.341   11.2
                          C1C2 + C2C2 vs. C1C1   9                   1.68 \[1.18,2.38\]\*      2.87                        0.004   R   0.000   69.9
                          C2C2 vs. C1C2 + C1C1   9                   1.36 \[0.71,2.58\]        0.93                        0.354   F   0.443   0.0
                          C2 vs. C1              14                  1.52 \[1.14,2.02\]\*      2.87                        0.004   R   0.000   74.8
  Hispanic                                                                                                                                     
                          C1C2 vs. C1C1          3                   1.02 \[0.72,1.43\]        0.08                        0.935   F   0.594   0.0
                          C2C2 vs. C1C1          3                   1.44 \[0.27,7.67\]        0.42                        0.672   F   0.669   0.0
                          C1C2 + C2C2 vs. C1C1   4                   1.04 \[0.76,1.44\]        0.27                        0.789   F   0.792   0.0
                          C2C2 vs. C1C2 + C1C1   3                   1.40 \[0.26,7.46\]        0.4                         0.692   F   0.663   0.0
                          C2 vs. C1              3                   1.04 \[0.75,1.44\]        0.23                        0.816   F   0.608   0.0
  **Disease**                                                                                                                                  
  CP                                                                                                                                           
                          C1C2 vs. C1C1          3                   1.54 \[1.04,2.27\]\*      2.14                        0.032   F   0.215   34.9
                          C2C2 vs. C1C1          3                   1.32 \[0.35,5.00\]        0.40                        0.687   F   0.478   0.0
                          C1C2 + C2C2 vs. C1C1   5                   1.45 \[1.10,1.91\]        2.61                        0.009   F   0.281   21.0
                          C2C2 vs. C1C2 + C1C1   3                   1.26 \[0.33,4.78\]        0.33                        0.738   F   0.496   0.0
                          C2 vs. C1              8                   1.38 \[1.10,1.73\]\*      2.82                        0.005   F   0.226   25.4
  CL/P                                                                                                                                         
                          C1C2 vs. C1C1          12                  1.60 \[1.16,2.20\]\*      2.89                        0.004   R   0.010   55.7
                          C2C2 vs. C1C1          11                  1.64 \[0.88,3.04\]        1.57                        0.116   F   0.457   0.0
                          C1C2 + C2C2 vs. C1C1   11                  1.46 \[1.09,1.95\]\*      2.55                        0.011   R   0.001   62.7
                          C2C2 vs. C1C2 + C1C1   11                  1.45 \[0.82,2.78\]        1.25                        0.211   F   0.545   0.0
                          C2 vs. C1              17                  1.29 \[1.01,1.66\]\*      2.03                        0.042   R   0.000   63.1
  **Source of control**                                                                                                                        
  HB                                                                                                                                           
                          C1C2 vs. C1C1          10                  1.84 \[1.32,2.56\]\*      3.58                        0.000   R   0.019   54.7
                          C2C2 vs. C1C1          10                  2.96 \[1.35,2.70\]\*      4.70                        0.000   F   0.965   0.0
                          C1C2 + C2C2 vs. C1C1   10                  1.99 \[1.35,2.70\]\*      3.66                        0.000   R   0.007   60.1
                          C2C2 vs. C1C2 + C1C1   10                  2.38 \[1.06,5.55\]\*      5.17                        0.000   F   0.968   0.0
                          C2 vs. C1              14                  1.63 \[1.22,2.18\]\*      3.28                        0.001   R   0.001   63.0
  PB                                                                                                                                           
                          C1C2 + C2C2 vs. C1C1   3                   0.99 \[0.79,1.24\]        0.10                        0.917   F   0.549   0.0
                          C2 vs. C1              3                   1.00 \[0.83,1.20\]        0.02                        0.986   F   0.778   0.0

^\*^OR had statistical significance with corresponding 95% CI not including 1. F: Fixed effect model; R: Random effect model.

In the subgroup analysis according to disease type, the ORs of the heterozygote comparison, dominant and allelic model with CL/P are statistically significant (C1C2 vs C1C1: OR = 1.60, 95% CI = 1.16-2.20; C2C2 + C1C2 vs C1C1: OR = 1.46, 95% CI = 1.09-1.95; C2 vs C1: OR = 1.29, 95% CI = 1.01-1.66). For the CP, the significant results were observed in heterozygote comparison, dominant and allelic model (C1C2 vs C1C1: OR = 1.54, 95% CI = 1.04-2.27; C2C2 + C1C2 vs C1C1: OR = 1.45, 95% CI = 1.10-1.19; C2 vs C1: OR = 1.38, 95% CI = 1.10-1.73).

In the subgroup analysis by control characteristics, the ORs of the heterozygote comparison, homozygote, dominant, recessive and allelic model for the hospital-based control are statistically significant (C1C2 vs C1C1: OR = 1.84, 95% CI = 1.32-2.56; C2C2 vs C1C1: OR = 2.96, 95% CI = 1.35-2.70; C2C2 + C1C2 vs C1C1: OR = 1.99, 95% CI = 1.35-2.70; C2C2 vs C1C2 + C1C1: OR = 2.38, 95% CI = 1.06-5.55; C2 vs C1: OR = 1.63, 95% CI = 1.22-2.18). While, no statistically significant association was found in population-based controls.

Heterogeneity between studies was observed in overall comparisons and also subgroup analyses. Thus, meta-analyses were performed using random-effect models (Table [2](#T2){ref-type="table"}).

To explore potential sources of heterogeneity in this meta-analysis, meta-regression analyses were implemented. The covariates included ethnicity and source of control. In all of the heterozygote comparison, homozygote, dominant, recessive and allelic models, above potential factors were probably not the major sources of heterogeneity (P-values were all \>0.05 or near 0.05). The heterogeneity might attribute to other factors, the insufficient data limited to identify their sources only using meta-regression.No publication bias was detected by either the inverted funnel plot or Egger's test. The shapes of the funnel plots seemed approximately symmetrical and P values of the Egger' tests were not statistical significant (P values were all \>0.05). Figure [5](#F5){ref-type="fig"} and Figure [6](#F6){ref-type="fig"} showed the funnel plot under the heterozygote comparison model (C1C2 versus C1C1) and the allelic model (C2 versus C1).

![Funnel plot under the heterozygote comparison model (C1C2 versus C1C1).](1472-6831-14-88-5){#F5}

![Funnel plot under the allelic model (C2 versus C1).](1472-6831-14-88-6){#F6}

Discussion
==========

The individual susceptibility plays an important role in the development of most diseases. Therefore, the studies of genetic susceptibility are helpful for disease prevention, diagnosis, and treatment.

TGFA is a well characterized mammalian growth factor. Previous studies found that although TGFA is expressed in mice during palatogenesis and mice with a null mutation of the TGFA gene have abnormal skin, hair, and eyes, but they do not have CL/P \[[@B38],[@B39]\]. TGFA is a likely ligand for epidermal growth factor receptor and newborn epidermal growth factor receptor-negative/-negative mice have high incidence of CL/P which may explain the association between TGFA polymorphisms and CL/P \[[@B40]\]. In 1989, it was firstly published that the TGFA Taq I polymorphism contributed to the development CL/P in humans. From then on, a growing number of studies have been done to examine the relationship between TGFA Taq I polymorphism and the risks of CL/P. However, the results are not consistent. In order to better understand the association, we subjected previously published data to meta-analysis to evaluate genetic associations between the TGFA Taq I polymorphism and CL/P susceptibility.

Through this meta-analysis we found that TGFA Taq I polymorphism increased the risk of CL/P. Mitchell adopted a reappraisal and showed that there was a statistically significant association between TGFA and CL/P, However, there was evidence of significant heterogeneity from different studies, regarding an association between genetic variation at the TGFA locus and CL/P remains inconclusive \[[@B41]\]. A meta-analysis of gene-environment interaction showed the suggestive evidence for gene-environment interaction between the infant's genotype at the Taq1 marker in TGFA and maternal smoking was limited to CP \[[@B42]\]. Meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers, including relatively novel or uncharacterized genes such as TGFA \[[@B43]\]. These results of systematic reviews in some extent support the findings in the present meta-analysis.

In order to reduce heterogeneity, we performed the stratified analyses. It is well know that the incidence of most genetic polymorphisms could vary between different ethnic populations and the wide range in TGFA Taq I allele frequencies across different studies suggests the heterogeneity between populations may exist \[[@B28]\]. In the subgroup analysis by ethnicity, we found that TGFA Taq I polymorphism increased the risk of CL/P in Caucasian population, which agreed with Ardinger and colleagues \[[@B12]\], Shiang and colleagues \[[@B20]\], Hwang and colleagues \[[@B22]\], Chenevix-Trench and colleagues \[[@B18]\], Holder and colleagues \[[@B17]\], and disagreed with Lidral and colleagues \[[@B27]\], \[[@B28]\], Stoll and colleagues \[[@B25]\] and Christensen and colleagues \[[@B11]\]. In the subgroup analysis by disease type, we found the ORs of different disease type were statistically significant, which suggested disease type was not mainly result the heterogeneity. In the subgroup analyses of control characteristics, only the ORs of hospital-based control groups were statistically significant. Therefore, subgroup analyses suggested that ethnicity and control characteristics might contribute to the heterogeneity in this meta-analysis. The meta-regression analyses suggested that ethnicity or control characteristics were probably not the major sources of heterogeneity. The heterogeneity might attribute to other factors. The insufficient data are limited to identify the source of heterogeneity only using meta-regression.

Despite trying our best to perform a comprehensive meta-analysis, some limitations exist in our study. Although the results for publication bias in our study were not statistically significant, our analysis used published international studies, which could arose publication bias. Lack of the original data of available studies limited our further evaluation of potential interactions, such as age, gender, family history, environmental factors and lifestyle. There were not significant results in stratified analyses among African and Hispanic population, because there were too few studies after stratifying. Therefore, more studies are needed to provide more evidence on the association between TGFA polymorphism and CL/P in different ethnic populations.

Although CL/P is a complex disease, our study provided evidence showing the important role of TGFA genes polymorphisms in the development of CL/P, genetic factors determining disease susceptibility and severity may facilitate personalized medicine. Further understanding of the interactions between genetic regulatory mechanisms is critical for discovering new therapies for managing human CL/P. Specifically, targeted therapy about the polymorphisms of related genes might be a promising avenue for future CL/P diagnosis and treatment.

In summary, our meta-analysis supports that the TGFA Taq I polymorphism is more likely to contribute to the susceptibility of CL/P, especially in the subgroup of Caucasian population.

Conclusion
==========

TGFA Taq I polymorphism may be associated with the risk of CL/P.
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